Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
Project Number5I01CX001957-02
Contact PI/Project LeaderCHAKRAVORTY, SUBHAJIT
Awardee OrganizationPHILADELPHIA VA MEDICAL CENTER
Description
Abstract Text
Abstract
Alcohol Use Disorder (AUD) and insomnia are both more prevalent among Veterans than in the general
population. While insomnia is 3-9 times more prevalent in AUD than in the general population, patients with
comorbid AUD and insomnia suffer from higher severity of AUD with increased alcohol craving, reduced quality
of life, impaired interpersonal functioning, higher risks for suicidal behavior and relapse during early
abstinence. There are limited options to treat drinking behavior and insomnia due to side effect profile
(disulfiram) or only modest impact on drinking outcomes (naltrexone and acamprosate). Topiramate (TOP), an
FDA-approved medication for seizures and migraines, showed moderate effect sizes in achieving abstinence
and decreasing craving, when compared to placebo, in a recent meta-analysis. However, TOP therapy did not
provide clinical improvement in objective sleep or subjective insomnia. Furthermore, hypnotic medication
treatments with trazodone, gabapentin, and ramelteon have shown variable impact for sleep disturbance and
abstinence. By contrast, all four studies evaluating Cognitive Behavioral Therapy for Insomnia (CBT-I) have
shown a large magnitude of effect for treating insomnia but with minimal to no effect on abstinence. Thus,
combining TOP and CBT-I will strengthen their recovery and improve their overall functioning. This
combination treatment will be the first personalized intervention in treating Veterans with AUD and comorbid
insomnia.
A sample of treatment-seeking Veterans with AUD (N=174) will be initially treated with TOP 200 mg a
day for six weeks, and then randomized to receive either CBT-I (N=87) or Sleep Hygiene Education (SHE, a
behavioral placebo intervention) (N=87) weekly for the next eight weeks. We will conduct CBT-I following our
standard protocol using 30-minute sessions to deliver its components (Sleep Restriction, Stimulus Control,
Sleep Hygiene and Cognitive Therapy). A post-intervention visit will be conducted eight weeks after the
intervention phase. The primary outcome measure will be the Percent Days Abstinent (as computed from the
Time Line Follow Back interview) and the insomnia severity (as assessed using the Insomnia Severity Index).
Also, we will track other aspects of alcohol use, sleep and daily functioning using TLFB, PACS, sleep diaries,
BDI, and the STAI to test whether successful treatment of drinking and insomnia will be associated with better
clinical outcomes in AUD. It is hypothesized that in Veterans with AUD, the combination of TOP+CBT-I, as
compared to TOP+SHE group, will lead to 1) a more significant percentage of days abstinent from alcohol, and
2) superior sleep-related outcomes along with pre-post treatment effect sizes comparable to the meta-analytic
norms. If these hypotheses are supported, the findings will need to be validated in a larger multi-center trial. If
validated, the findings would support: 1) including insomnia treatment as a standard component of the initial
protocol for treating AUD comorbid with insomnia, and 2) using TOP+CBT-I combination treatment to manage
this subpopulation of AUD patients.
Public Health Relevance Statement
Project Narrative
Alcohol Use Disorder (AUD) and insomnia are more prevalent in Veterans than in the general community.
Furthermore, insomnia is comorbid in 36-91% of individuals with AUD and jeopardizes recovery by increasing
their risk for relapse and complicating their clinical profile. The VA/DoD guidelines recommend four medications
for the treatment of AUD. Among them, topiramate (TOP) has demonstrated promise in improving abstinence
and decreasing heavy drinking but without any clinical improvement in sleep continuity. The recommended
treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I), and it has shown efficacy in
improving insomnia but with minimal benefit in improving abstinence. The proposed study will evaluate whether
augmenting TOP with CBT-I bolsters recovery in AUD, by improving abstinence and decreasing insomnia. If this
strategy shows good clinical results and the findings are replicated in a multi-center trial then the combination of
TOP with CBT-I should be considered a standard component of the initial management of AUD with insomnia.
No Sub Projects information available for 5I01CX001957-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5I01CX001957-02
Patents
No Patents information available for 5I01CX001957-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5I01CX001957-02
Clinical Studies
No Clinical Studies information available for 5I01CX001957-02
News and More
Related News Releases
No news release information available for 5I01CX001957-02
History
No Historical information available for 5I01CX001957-02
Similar Projects
No Similar Projects information available for 5I01CX001957-02